← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Xfibra, Inc.
Del Mar, CA
$10,950,404
Total funding
8
Grants
Funding over time
peak $5.2M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$6,113,670 · 2
NIH$4,836,734 · 6
By mechanism
—$6,113,670 · 2
R44$3,901,921 · 3
R41$934,813 · 3
Investigators at Xfibra, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A FIRST-IN-CLASS, AGNOSTIC, HOST-DIRECTED PRECISION MEDICINE TREATMENT FOR ACUTE RESPIRATORY DISTRESS SYNDROME$3,421,180
· FY2025 · Defense Health Agency
PULMONARY FIBROSIS: NOVEL THERAPEUTIC DEVELOPMENT$2,692,490
· FY2020 · Defense Health Agency
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$1,326,982
R44 · FY2020 · HL
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$1,136,111
R44 · FY2020 · DK
An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants.$999,601
R44 · FY2024 · AI
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis$316,111
R41 · FY2015 · HL
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS$311,803
R41 · FY2014 · HL
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS$306,899
R41 · FY2013 · DK
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$224,967
R44 · FY2019 · HL
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$214,260
R44 · FY2019 · DK